In sufferers with castration-resistant prostate cancer.

Heyman, Ph.D., CEO and President of Aragon.’ ARN-509 can be an androgen receptor antagonist that inhibits nuclear DNA and translocation binding of the receptor, thereby modulating expression of genes that travel prostate cancer growth.. Aragon initiates dosing in ARN-509 Stage 1/2 clinical trial for castration-resistant prostate cancer Aragon Pharmaceuticals today announced the dosing of the initial patient in a Phase 1/2 clinical trial of the company’s lead compound, ARN-509, in sufferers with castration-resistant prostate cancer . The Phase 1 portion of the study, being conducted at the Memorial Sloan-Kettering Cancer Center in New York City, is an open-label, dose-escalating trial evaluating the tolerability and safety of ARN-509 in sufferers with progressive metastatic castration-resistant prostate cancer.What the researchers found is that the checkpoint mutants disregard this transmission. Using the metaphor above, the driver of the car can't take his foot from the accelerator and keeps heading until his engine sputters to an end. While this won't damage an automobile engine, it's catastrophic for DNA. Related StoriesTumour DNA in the blood can accurately monitor cancer in real timeDNA examining for Down's syndrome could potentially save lives of unborn babiesStudy reviews discovery of new course of DNA repair enzyme These mutant cells keep trying to reproduce their DNA, unwinding the strands, until the DNA strands reach a ‘collapse stage’ where they break – arguably the worst sort of damage that can be done to a cell.